CCL23在肝细胞癌中的表达及其对预后的影响

肝脏 ›› 2019, Vol. 24 ›› Issue (4): 368-372.

CCL23在肝细胞癌中的表达及其对预后的影响

汪建业, 赵之聪, 侯嘉杰, 夏强

200127 上海交通大学医学院附属仁济医院肝脏外科

收稿日期:2018-12-02 出版日期:2019-04-30 发布日期:2020-04-07
通讯作者: 夏强,Email:xiaqiang@shsnu.edu.cn

Expression of CCL23 in hepatocellular carcinoma and its effect on prognosis

WANG Jian-ye, ZHAO Zhi-cong, HOU jia-jie, XIA Qiang

Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China

Received:2018-12-02 Online:2019-04-30 Published:2020-04-07
Contact: XIA Qiang, Email: xiaqiang@shsnu.edu.cn

摘要/Abstract

摘要： 目的研究肝细胞癌组织中的表达变化最显著的趋化因子及其对于肝癌患者预后的临床价值。方法通过使用公共数据库筛选出肝细胞癌及癌旁组织中差异最明显的趋化因子—CCL23,使用qPCR以及免疫组化验证其在肝细胞癌组织中的表达,并分析CCL23表达与临床病理特征、肝癌患者预后的关系。结果通过公共数据库发现多种趋化因子在肝癌中发生显著改变,而CCL23在公共数据库及患者的肝细胞癌组织中均显著降低(TCGA、GSE14520、GSE25097:P<0.01,GE64041:P=0.0003,GSE57957:P=0.0001,本院:P<0.01),肝癌组织中CCL23高表达者术后总体生存期及无复发生存期均显著延长(总体生存期:TCGA:P=0.0026,GSE14520:P=0.0014,本院:P<0.01;无复发生存期:TCGA:P=0.0306,GSE14520:P=0.0189,本院:P<0.01)。结论肝癌组织中的CCL23表达显著降低,可预测肝细胞癌患者预后并可作为临床治疗的潜在靶标。

关键词: 肝细胞癌, 公共数据库, 趋化因子, CCL23, 预后

Abstract: Objective To investigate the most significant chemokine of expression in hepatocellular carcinoma(HCC) and its clinical value in prognosis of HCC patients. Methods CC chemokine ligand 23(CCL23) was screened as the the most significant chemokine of expression in hepatocellular carcinoma and adjacent tissues using a public databases. Its expression was verified in HCC tissues in our hospital by quantitative polymerase chain reaction and immunohistochemistry staining. Then the correlation between the level of CCL23 and the clinicopathological characteristics, the prognosis of HCC patients was investigated. Results CCL23 was significantly downregulated in liver cancer tissues in public databases and HCC patients in our hospital(TCGA, GSE14520, GSE25097: P<0.0001, GE64041: P=0.0003, GSE57957: P=0.0001, our hospital: P<0.0001). The patients with higher level of CCL23 in tumor tissues had longer overall survival period(TCGA: P=0.0026, GSE14520: P=0.0014, our hospital: P<0.0001) and recurrence-free survival period(TCGA: P=0.0306, GSE14520: P=0.0189, our hospital: P<0.0001). Conclusion The expression of CCL23 in liver cancer tissues is significantly decreased, which may predict the prognosis of HCC patients and act as a potential target for clinical treatment.

Key words: Hepatocellular carcinoma, Public database, Chemokine, CC chemokine ligand 23, Prognosis

汪建业, 赵之聪, 侯嘉杰, 夏强. CCL23在肝细胞癌中的表达及其对预后的影响[J]. 肝脏, 2019, 24(4): 368-372.

WANG Jian-ye, ZHAO Zhi-cong, HOU jia-jie, XIA Qiang. Expression of CCL23 in hepatocellular carcinoma and its effect on prognosis[J]. Chinese Hepatolgy, 2019, 24(4): 368-372.

参考文献

[1] Zlotnik A, Yoshie O. Chemokines a new classification system and their role in. Immunity,2000,12:121-127.
[2] Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity,2012,36:705-716.
[3] Youn BB-S, Zhang SM, Broxmeyer HE, et al. Characterization of CKβ8 and CKβ8-1: Two alternatively spliced forms of human β-Chemokine, chemoattractants for neutrophils, monocytes, and lymphocytes, and potent agonists at CC chemokine receptor 1. Blood,1998,91:3118-3126.
[4] Patel BVP, Kreider BL, Li Y, et al. Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. J Exp Med,1997,185:1163–1172.
[5] B N, DK M, GW B, et al. Dendritic cells and MPIF-1 chemotactic activity and inhibition of endogenous chemokine production by IFN-r and CD40 ligation. J Leukoc Biol,1999,65:822-828.
[6] Zhang X, Wan JX, Ke ZP, et al. TMEM88, CCL14 and CLEC3B as prognostic biomarkers for prognosis and palindromia of human hepatocellular carcinoma. Tumour Biol,2017,39:1-9.
[7] Wang Y, Bai Z, Niu Z, et al. Transcriptomic analyses of chemokines reveal that down-regulation of XCR1 is associated with advanced hepatocellular carcinoma. Biochem Biophys Res Commun,2018,496:1314-1321.
[8] Liang Z, Brooks J, Willard M, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun,2007,359:716-722.
[9] Lin L, Han MM, Wang F, et al. CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression. Cell Death Dis,2014,5:e1488.
[10] Matsubara T, Ono T, Yamanoi A, et al. Fractalkine-CX3CR1 axis regulates tumor cell cycle and deteriorates prognosis after radical resection for hepatocellular carcinoma. J Surg Oncol,2007,95:241-249.
[11] Uchida H, Iwashita Y, Sasaki A, et al. Chemokine receptor CCR6 as a prognostic factor after hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol,2006,21:161-168.
[12] Han I-S, Ra J-S, Kim M-W, et al. Differentiation of CD34+ cells from human cord blood and murine bone marrow is suppressed by C6 b-Chemokines. Mol Cells,2003,15:176-180.
[13] Li Y, Wu J, Zhang P. CCL15/CCR1 axis is involved in hepatocellular carcinoma cells migration and invasion. Tumour Biol,2016,37:4501-4507.
[14] Yuan Y, Liu J, Liu Z, et al. Chemokine CCL3 facilitates the migration of hepatoma cells by changing the concentration intracellular Ca. Hepatol Res,2010,40:424-431.

[1]	张军建, 张矿召. 丙型肝炎病毒NS3非结构蛋白对人胚胎肝细胞L02细胞增殖以及端粒酶活性的研究[J]. 肝脏, 2020, 25(2): 135-137.
[2]	杜品清, 刘云国, 胡毅. 肝细胞癌微血管浸润的CT、MRI影像特征及其诊断价值[J]. 肝脏, 2020, 25(2): 138-141.
[3]	魏媛媛, 田艳红, 李红静, 张浩, 李木松. RNA、lnc-EGFR对肝细胞癌免疫逃避调节的相关性[J]. 肝脏, 2020, 25(2): 142-145.
[4]	李友学. 三维超声造影对肝癌消融治疗后残留病灶的诊断价值[J]. 肝脏, 2020, 25(2): 175-180.
[5]	周志莲, 邵春燕, 刘向东. 肝细胞癌行TACE治疗术后并发症的原因分析和处理体会[J]. 肝脏, 2020, 25(2): 191-193.
[6]	贾磊, 李豪, 白鸿太, 陈国勇, 魏思东. CD34和Ki67的表达预测肝癌术后复发的风险[J]. 肝脏, 2020, 25(2): 197-198.
[7]	原庆会, 何伟. Vimentin在肝细胞癌组织中的表达及其与临床预后的关系[J]. 肝脏, 2020, 25(2): 199-201.
[8]	李祥苏, 金星星, 王冬冬, 吴旭东. 血清LECT2检测对肝细胞癌诊断的意义[J]. 肝脏, 2020, 25(1): 71-72.
[9]	刘蕾, 王哲, 赵静, 郭广春, 王耿泽. 多层螺旋CT三期灌注扫描联合CT血管造影对肝细胞癌术后复发监测的价值[J]. 肝脏, 2020, 25(1): 81-82.
[10]	李茂胜, 谢微波. 肝细胞癌和局灶性结节增生CT定量参数差异及临床鉴别意义[J]. 肝脏, 2019, 24(8): 907-910.
[11]	姚本来, 李晓明, 李芳飘, 姚立鹏. Treg和IL-10在肝癌组织的表达及评估预后的价值[J]. 肝脏, 2019, 24(8): 921-922.
[12]	黎李萍, 伍民生, 唐艳芳, 刘品晶, 陈盛奎. 重症病毒性肝炎患者医院感染病原菌特征及其与预后的关系[J]. 肝脏, 2019, 24(8): 923-924.
[13]	李瑞, 周长东. ERCP术后行LC手术时机的选择对胆囊合并胆总管结石患者肝功能、炎性反应及预后的影响[J]. 肝脏, 2019, 24(8): 938-940.
[14]	胡朝峰, 童钟, 黄俊. 功能性残肝体积预测肝细胞癌患者术后肝功能不全的可行性[J]. 肝脏, 2019, 24(7): 752-755.
[15]	贾铭丽, 汪云. 血清淀粉样蛋白A联合腺苷脱氨酶在自身免疫性肝炎的价值分析[J]. 肝脏, 2019, 24(7): 773-776.